OnCo

Stay in the loop

Leave your email and OnCo will write when something big changes in cancer research. No spam, one click to unsubscribe.

Email updates open shortly. Until then, press Watch on any page to keep it on your list.

Cancers & treatments·Sequencing

Oesophageal and junctional adenocarcinoma: lines of therapy

Cancer page →

4 standard-of-care settings across 4 lines and 2 biomarker subgroups. Rows come from the cancer page's standard of care; the grid places each on its line and subgroup.

LineAll comersHER2
Locally advanced1·
Advanced, first line1·
Third line and beyond·1
Other settings1·

Locally advanced

SubgroupSettingApproachProducts and trialsEvidence
All comersLocally advancedPerioperative FLOT (docetaxel, oxaliplatin, fluorouracil, leucovorin) and oesophagectomy, preferred over CROSS after ESOPEC; chemoradiation where chemotherapy is not tolerated.
FLOT (5-FU, leucovorin, oxaliplatin, docetaxel)DocetaxelOxaliplatinFluorouracil (5-FU)CROSS
86

Advanced, first line

SubgroupSettingApproachProducts and trialsEvidence
All comersAdvanced, first lineNivolumab or pembrolizumab with platinum-fluoropyrimidine chemotherapy for PD-L1-positive tumours; trastuzumab with chemotherapy (and pembrolizumab) for HER2-positive tumours; zolbetuximab with chemotherapy for claudin 18.2-positive tumours.
NivolumabPembrolizumabTrastuzumabZolbetuximabHER2PD-L1Claudin 18.2
98

Third line and beyond

SubgroupSettingApproachProducts and trialsEvidence
HER2Later linesTrastuzumab deruxtecan for HER2-positive disease; ramucirumab with paclitaxel; trifluridine-tipiracil.
Trastuzumab deruxtecanRamucirumabPaclitaxel / nab-paclitaxel
97

Other settings

SubgroupSettingApproachProducts and trialsEvidence
All comersBarrett's oesophagusEndoscopic surveillance; radiofrequency ablation or endoscopic resection for dysplasia and early cancer.
Endoscopic resection (EMR / ESD)
40

Sequence and caution pairings

CautionApproved
Caution: DXd ADC + agents with pneumonitis risk

Enhertu and its DXd cousins can inflame the lungs; combining them with immunotherapy, radiation, or mTOR inhibitors stacks that risk.

Lines and subgroups are parsed from the setting text of each standard-of-care row and can misclassify an unusual phrasing; the row’s own setting is always shown. Guideline chips reflect the NCCN category and ESMO-MCBS grade recorded on the cancer page, checked on its stated date. Not medical advice.